Moreover, in vitro studies indicate that combined immunotherapy with a vaccine and an anti-CTLA-4 monoclonal antibody can significantly enhance the anti-tumour immune response compared to the vaccine or monoclonal antibody alone, and MUC1 can be a target for CAR-T therapy in HNSCC [582]. This evidence concerns the gene MUC1 and head and neck squamous cell carcinoma.